All information on this page is subject to MCDSA’s disclaimer.
Cannabidiol (CBD) is one of many cannabinoid molecules produced by Cannabis, second only to THC in abundance. These plant-derived cannabinoids, or phytocannabinoids (phyto = plant in Greek), are characterized by their ability to act on the cannabinoid receptors that are part of our endocannabinoid system. While THC is the principal psychoactive component of Cannabis and has certain medical uses, CBD stands out because it is both non-psychoactive and displays a broad range of potential medical applications. These properties make it especially attractive as a therapeutic agent.
Perhaps the most remarkable thing about CBD is the sheer number and variety of its potential therapeutic applications. It is important to recognize that each application may be supported by different levels of evidence. These range from ongoing clinical trials evaluating its efficacy in the treatment of human disorders, to animal studies investigating its behavioral and physiological effects, to in vitro work (test tube experiments) measuring its pharmacological interactions and mechanisms of action. Each type of study comes with its own strengths and weaknesses.
Clinical trials allow us to draw conclusions about the safety and effectiveness of potential therapeutic agents in humans, while animal studies and in vitroexperiments allow researchers to explore their biological actions in greater detail. However, because the latter class of studies are not conducted in humans, the results don’t always lead to the clinical application that we hope for—the majority of drugs that start in human clinical trials never become approved. Nonetheless, animal studies provide us with a strong foundation of biological knowledge, and are where the initial breakthroughs in research are made.
CBD is famous for the promise it holds for treating treatment-resistant forms of childhood epilepsy. A number of clinical trials, testing the efficacy of CBD in human epilepsy patients, are currently underway. But there is also evidence, mainly from animal studies and in vitro experiments, that CBD may have neuroprotective, anti-inflammatory and analgesic (pain-relieving) properties, and potential therapeutic value in the treatment of motivational disorders like depression, anxiety, and addiction.
What’s the biological basis for this wide range of potential medical uses? A key part of the answer lies in CBD’s promiscuous pharmacology—its ability to influence a wide range of receptor systems in the brain and body, including not only cannabinoid receptors but a host of others.
The brain contains large numbers of highly specialized cells called neurons. Each neuron connects to many others through structures called synapses. These are sites where one neuron communicates to another by releasing chemical messengers known as neurotransmitters (Figure 1).
A neuron’s sensitivity to a specific neurotransmitter depends on whether or not it contains a receptor that “fits” that transmitter, like an electrical socket fits a plug. If a neuron contains receptors that match a particular neurotransmitter, then it can respond directly to that transmitter. Otherwise, it generally can’t. All neurons contain multiple neurotransmitter receptors, allowing them to respond to some neurotransmitters but not others.
Brain receptors are not only sensitive to neurotransmitters produced naturally within the brain, like dopamine or serotonin, but also chemical messengers produced outside the body, such as plant cannabinoids like THC or CBD. So when you ingest an edible or inhale some vapor, you’re allowing compounds originally produced by a plant to enter your body, travel through your bloodstream, and enter your brain. Once they arrive, these plant-derived compounds can influence brain activity by interacting with receptors on neurons. But they don’t interact with all neurons, just the ones that have the appropriate receptors.
Although it is a cannabinoid, CBD does not directly interact with the two classical cannabinoid receptors (CB1 and CB2). Instead, it affects signaling through CB1 and CB2 receptors indirectly. This partly explains why, in contrast to THC, CBD is non-psychoactive (see Bruce Barcott’s article tomorrow). In addition to its indirect influence on the CB1 and CB2 receptors, CBD can increase levels of the body’s own naturally-produced cannabinoids (known as endocannabinoids) by inhibiting the enzymes that break them down.
Even more intriguing: CBD also influences many non-cannabinoid receptor systems in the brain, interacting with receptors sensitive to a variety of drugs and neurotransmitters (Figure 2). These include opioid receptors, known for their role in pain regulation. Opioid receptors are the key targets of pharmaceutical-grade pain killers and drugs of abuse such as morphine, heroin, and fentanyl. CBD can also interact with dopamine receptors, which play a crucial role in regulating many aspects of behavior and cognition, including motivation and reward-seeking behavior.
This raises the intriguing possibility that CBD’s ability to influence either the opioid or dopamine receptors may underlie its ability to dampen drug cravings and withdrawal symptoms, effects directly relevant to the treatment of addiction (see Bailey Rahn’s article later this week). However, we can’t say for sure at this point; more research on CBD’s interactions with the opioid and dopamine receptor systems is still needed.
CBD’s therapeutic potential with respect to addiction also extends to the serotonin system. Animal studies have demonstrated that CBD directly activates multiple serotonin receptors in the brain. These interactions have been implicated in its ability to reduce drug-seeking behavior. CBD’s influence on the serotonin system may also account in part for its anti-anxiety properties, which have been robustly demonstrated across both human and animal studies (see Jeremy Kossen’s article later this week).
CBD’s ability to target a specific serotonin receptor, the serotonin 1A receptor, is associated with a remarkable range of therapeutic possibilities. Professor Roger Pertwee, a pharmacologist from the University of Aberdeen, spoke with Leafly about this aspect of CBD biology.
“It’s apparent ability to enhance the activation of serotonin 1A receptors supports the possibility that it could be used to ameliorate disorders that include: opioid dependence, neuropathic pain, depression and anxiety disorders, nausea and vomiting (e.g. from chemotherapy), and negative symptoms of schizophrenia,” he said. “One big unanswered question is what the human clinical relevance and importance of each of these potential therapeutic uses of CBD, identified solely by examining data from non-human preclinical research, actually is.”
Given that these possibilities come mainly from animal studies, more research will be needed before we can think seriously about human applications.